ResMed Director Increases Stake with stock โAward
Sydney, Australia โ- ResMed Inc. (AU:RMD) Director Christopher DelOrefice recently acquired 1,073 shares of the company’s common stock thru Restrictedโ Stockโ Units โ(RSUs). The shares vest either by November โ2026 or atโฃ the โขnext annual stockholders’ meeting, accordingโค to a recent disclosure.
This transaction signals a continued alignment of leadership interests with those of ResMed shareholders. RSUs are a form โคofโข compensation frequently enough used to incentivize executives and directors,tying their financial successโ to the โขcompany’s performance.
ResMedโ Inc. โis a global leader in the healthcare industry, specializing in the growth and manufacturing of devices and cloud-connectedโ solutionsโค for the treatment โof sleep disorders, including sleep apnea, and other respiratory conditions. โฃ
As โคof today, AU:RMD maintains a “Buy” rating โfrom analysts with a price target of A$42.00.Theโ company’s current market capitalization is A$56.69B, with an average trading volume of 1,214,271 shares.
Investors can โขfind further analysis of ResMed Inc. CHESS Depositary interests on aโค ratio โฃof 10 CDIs per ord.sh at https://www.tipranks.com/stocks/au:rmd.